Alzheimer’s Disease – New Research Finds that Glutamate May Improve Cognitive Function

Cell Signaling Technologies, Inc. is a privately held biotechnology firm that develops, manufactures, and delivers therapeutic antibodies, ELISA Kits, ChIP kits, and other associated reagents necessary to demonstrate the cell signaling mechanisms that affect human disease. The Cytokines arrayed against the herpes virus in the Cytokine family are manufactured by this company. The Cytokine antibodies interfere with the entry signals of the herpes virus into cells and cause cellular death.

Cytokine and other compounds in the Cytokine family have been shown to have multiple roles in the nervous system and various diseases. For instance, the protein indicated by the Bioactive X-ray Fluorescent protein (BXRF) hscs is a compound that prevents neurocytic inflammatory processes and stimulates the neurotrophic factors that facilitate neurotransmission in the nervous system. This compound acts as a trophic switch. BXRF hscs is manufactured by a company called Biogenix. An expert panel was assembled to determine which compounds in the Cytokine family were most useful for treating diseases like Alzheimer’s. A consensus agreement was reached that BXRF was the most effective molecule for the treatment of Alzheimer’s, apart from a number of other compounds.

A second important compound B-cyclic AMP (BCAP) inhibits the intracellular signaling of voltage-sensitive potassium channels activated by NMDA. In Alzheimer’s, calcium influx into the cells can block the NMDA receptor, thus preventing the channel from being closed and/or opening. Similarly, external noise can activate calcium channels and lead to an increase in intracellular signaling strength. BCAP prevents this increase by deactivating the channels that are activated by external noise. The third Cytokine is not involved in the above-mentioned phenomenon and is therefore not useful for treating Alzheimer’s.

Studies have shown that poned structures within the cytoskeleton of neurons can be activated by trophic influences. These influences could either be NMDA or ATP. Neurons can also receive positive and negative inputs from other neurons. Neurotransmitters such as NMDA, ATP, glycogen, and noradrenalin send signals to the neurons. Neurons in the cortex then receive these signals and relay them to the rest of the body through the nutrient pathway, via the nutrient transport protein Fast Glycan.

Glutamate is an excitatory neurotransmitter that is essential for transmitting nerve impulses from one area of the brain to another. NMDA is released by the NMDA receptor when it is activated. It is thought that the increased level of NMDA and the increased level of Glycine are responsible for triggering a series of events leading to dyslexia described above. Glycine has its own role in the Glycation Cycle. In experiments with cultured neurons, amino acid supplementation decreased the amount of glutamate that was released during training and memory. It was shown that this supplementation did not affect the levels of NMDA receptors either.

The researchers showed that the increase in Glycine reduced the ability of the NMDA receptor to activate the non NMDA cells, and the decrease in Glycine led to the impairment of both learning and memory. This study is very promising. However, further studies are needed to determine whether these findings are relevant to humans and if they apply to Alzheimer’s disease and other similar forms of dementia. If this is true, it means that supplementation with Glutamate, the non-NMDA glutamate receptor agonist, might be useful for treating and possibly preventing Alzheimer’s disease, as the supplement prevents the Glycation Syndrome and is said to improve the insulin sensitivity of the brain. It is currently being studied in controlled studies.